Discovery Gateway to Reproductive Health Innovation
Agency
National Institutes of Health
Posted
Oct 20, 2026
Due Date
Oct 1, 2027
Description
<p>The <i>Eunice Kennedy Shriver</i> National Institute of Child Health and Human Development (NICHD) seeks to establish a single Discovery Gateway to Reproductive Health Innovation, a comprehensive knowledgebase designed to advance research on male and female indications such as preeclampsia, endometriosis, preterm birth, infertility, and uterine fibroids. This initiative will expand shared resources and essential infrastructure for the biomedical research community.<br><br>The Gateway will facilitate integration of existing clinical, pharmacogenomic, and multi-omic data in order to address critical knowledge gaps. By providing open-access, this web-based visualization platform will empower scientists to generate new insights that extend far beyond the scope of individual research efforts. Ultimately, the overarching goal is to catalyze the discovery of new treatments and cures. By identifying potential disease mechanisms, effector genes, biomarkers, and drug targets, the Gateway will drive the development of innovative commercial products and accelerate public-private partnerships.</p><p>The Discovery Gateway supports multiple implementation recommendations made by the Task Force on Research Specific to Pregnant Women and Lactating Women (PRGLAC; <a href="https://www.nichd.nih.gov/about/advisory/PRGLAC">https://www.nichd.nih.gov/about/advisory/PRGLAC</a>). Grant authorities that allow NICHD to forecast this opportunity are as follows: 42 U.S.C. 281 (Sec. 401); 42 U.S.C. 285g (Sec. 448); 42 USC 284h (Sec. 409D).</p>
AI Summary
Agency: National Institutes of Health
Details
- Notice ID
- 364126
- Solicitation Number
- RFA-HD-28-001
- Classification Code
- D
Want to track opportunities like this?
Sign up for Kontratar to get AI-powered opportunity matching, ranking, and alerts.
Get Started FreeRelated opportunities
- Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed)
National Institutes of Health
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
National Institutes of Health
- Research on System Support and Tools for Provider Training and Quality Monitoring for Suicide Preventive Care (RP1- Clinical Trial Optional)
National Institutes of Health
- Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed)
National Institutes of Health
- The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) Scientific Data Research Center (U24 Clinical Trial Not Allowed)
National Institutes of Health
- Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
National Institutes of Health
- George M. O’Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)
National Institutes of Health